PortalPublikationenCetuximab enhances the efficacy of bortezomib in squamous ce...

Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.

Standard

Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. / Wagenblast, Jens; Baghi, Mehran; Arnoldner, Christoph; Bisdas, Sotirios; Gstöttner, Wolfgang; Ackermann, Hanns; May, Angelika; Hambek, Markus; Knecht, Rainald.

in: J CANCER RES CLIN, Jahrgang 135, Nr. 3, 3, 2009, S. 387-393.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Wagenblast, J, Baghi, M, Arnoldner, C, Bisdas, S, Gstöttner, W, Ackermann, H, May, A, Hambek, M & Knecht, R 2009, 'Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.', J CANCER RES CLIN, Jg. 135, Nr. 3, 3, S. 387-393. <http://www.ncbi.nlm.nih.gov/pubmed/18830627?dopt=Citation>

APA

Wagenblast, J., Baghi, M., Arnoldner, C., Bisdas, S., Gstöttner, W., Ackermann, H., May, A., Hambek, M., & Knecht, R. (2009). Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. J CANCER RES CLIN, 135(3), 387-393. [3]. http://www.ncbi.nlm.nih.gov/pubmed/18830627?dopt=Citation

Vancouver

Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstöttner W, Ackermann H et al. Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. J CANCER RES CLIN. 2009;135(3):387-393. 3.

Bibtex

@article{2fa99e9570834b24aba20d5641b0900f,
title = "Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.",
abstract = "PURPOSE: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade) in combination with cetuximab in squamous cell carcinoma cell lines (SCC). METHODS: Dose-escalation studies were performed in five squamous cell carcinoma cell lines using bortezomib or cetuximab alone or in combination. Cell survival and growth inhibition were measured quantitatively using an MTT and LDH assay. RESULTS: Bortezomib alone showed a significant antiproliferative activity in all SCC cell lines (P <0.042), and the activity was further significantly enhanced by the addition of cetuximab (P <0.043). CONCLUSIONS: Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.",
author = "Jens Wagenblast and Mehran Baghi and Christoph Arnoldner and Sotirios Bisdas and Wolfgang Gst{\"o}ttner and Hanns Ackermann and Angelika May and Markus Hambek and Rainald Knecht",
year = "2009",
language = "Deutsch",
volume = "135",
pages = "387--393",
journal = "J CANCER RES CLIN",
issn = "0171-5216",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines.

AU - Wagenblast, Jens

AU - Baghi, Mehran

AU - Arnoldner, Christoph

AU - Bisdas, Sotirios

AU - Gstöttner, Wolfgang

AU - Ackermann, Hanns

AU - May, Angelika

AU - Hambek, Markus

AU - Knecht, Rainald

PY - 2009

Y1 - 2009

N2 - PURPOSE: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade) in combination with cetuximab in squamous cell carcinoma cell lines (SCC). METHODS: Dose-escalation studies were performed in five squamous cell carcinoma cell lines using bortezomib or cetuximab alone or in combination. Cell survival and growth inhibition were measured quantitatively using an MTT and LDH assay. RESULTS: Bortezomib alone showed a significant antiproliferative activity in all SCC cell lines (P <0.042), and the activity was further significantly enhanced by the addition of cetuximab (P <0.043). CONCLUSIONS: Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.

AB - PURPOSE: Proteasome inhibition has been shown to be effective in multiple myeloma and solid tumor models. In this in vitro study, we investigated the antitumor effect of bortezomib (Velcade) in combination with cetuximab in squamous cell carcinoma cell lines (SCC). METHODS: Dose-escalation studies were performed in five squamous cell carcinoma cell lines using bortezomib or cetuximab alone or in combination. Cell survival and growth inhibition were measured quantitatively using an MTT and LDH assay. RESULTS: Bortezomib alone showed a significant antiproliferative activity in all SCC cell lines (P <0.042), and the activity was further significantly enhanced by the addition of cetuximab (P <0.043). CONCLUSIONS: Our results indicate that cetuximab increases the cytotoxic activity of bortezomib in SCC cell lines. Combination therapy of SCC with bortezomib and cetuximab might be less toxic than conventional drug regimens used in the treatment of these tumors.

M3 - SCORING: Zeitschriftenaufsatz

VL - 135

SP - 387

EP - 393

JO - J CANCER RES CLIN

JF - J CANCER RES CLIN

SN - 0171-5216

IS - 3

M1 - 3

ER -